| Ytd | -59.36% | |
| 1y | -62.29% |
| Open | 0.79 | Prev Close | 0.75 | Low | 0.77 | High | 0.81 | Mkt Cap | 15.43M |
| Vol | 229.16K | Avg Vol | 507.23K | EPS | -0.66 | P/E | N/A | Forward P/E | -2.35 |
| Beta | 1.34 | Short Ratio | 0.64 | Inst. Own | 7.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.15 | 200-d Avg | 1.78 | 1yr Est | 21.33 |
DARE News
The article, titled, "An open-label, single-dose, randomized, parallel-group study of the safety
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's
View the video webcast here
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market
New NIH award will provide approximately $908,000 in year-long support of preclinical development, w
Video webcast now available here
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtu
The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation st
Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evalu
President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcomi
National recognition comes as Daré Bioscience advances a multi-product women's health strategy acros
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closi
SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.2 per share versus the Zacks Conse
Dare Bioscience (NASDAQ:DARE) released second-quarter financial results and hosted an earnings call
Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generat
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtu
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven
Live video webcast on Tuesday, July 14th, at 4:00 PM ETRegister here SAN DIEGO, July 09, 2026 (GLOBE
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding aw
The Phase 2 study is a randomized, placebo-controlled, double-blind trial designed to evaluate the s
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst
Dare Bioscience stock climbed after Phase 3 interim data for Ovaprene showed expected pregnancy rate
Second Positive DSMB Review Supports Continued Study ProgressInterim Phase 3 Results Support Ovapren
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.02) per share which beat the analyst
